Price To Earnings Ratio 50.54 | Sector PE 71.28 |
PB Ratio 6.83 | Sector PB 9.12 |
EPS 42.01 | Dividend Yield 0.49 |
Today's Volume 1.808 M | 5 Day Avg. Volume 909.381 K |
PEG Ratio 0.15 | Market Cap. ₹ 94,740.00 Cr. |
Lupin Limited is an Indian pharmaceutical company. The company manufactures, develops and markets a variety of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) worldwide. The company operates in the Cardiovascular, Diabetes, Asthma, Pediatric, CNS, Gastrointestinal, Anti-Infective and Non-Steroidal Anti-Inflammatory drug therapeutic segments and operates in the Anti-Tuberculosis and Cephalosporin segments. The company and its subsidiaries have manufacturing facilities in India, the United States, Mexico and Brazil, and trading and other ancillary and related activities also extend to global markets. Its complex generic portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol, among others. Its biosimilars include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim), and Etanercept.